Evidence map›Paper›PMID 42156610›Full record

ReviewInternational journal of clinical oncology2026

The dual role of gastric microbiota dysbiosis in gastric cancer progression and therapy.

Yuze Liu, Qiangzu Shao, Chunbo Zhang, Fan Zhang, Jie Liu, Yumin Li, Zeping Huang

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuze Liu *The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Qiangzu Shao *The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Chunbo ZhangThe Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Fan ZhangDepartment of Surgical Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Jie LiuDepartment of Surgical Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Yumin LiDepartment of Surgical Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Zeping HuangDepartment of Surgical Oncology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, China. Ldyy_huangzp@lzu.edu.cn.

Funding

Gansu Province Health Industry Science and Technology Innovation Major Projects GSWSKY2024-06Gansu Provincial Joint Scientific Research Fund Major Project 25JRRA1264National Natural Science Foundation of China 82460559the Cuiying Scientific and Technological Innovation Program of the Second Hospital of Lanzhou University CY2022-YB-A04the Cuiying Scientific and Technological Innovation Program of the Second Hospital of Lanzhou University CY2024-MS-B18the Cuiying Scientific and Technological Innovation Program of the Second Hospital of Lanzhou University No.CY2023-MS-B17
6 · The paper itself

Abstract

Gastric cancer (GC) ranks among the most prevalent malignant neoplasms globally and is one of the leading causes of cancer-related mortality. The gastric microbiota, as a crucial component of the human microecosystem, plays a pivotal role in maintaining human health through its ecological balance. In recent years, with the advancement of technologies such as metagenomics, the dysbiosis of gastric microbiota has increasingly become a focal point of research, particularly in understanding its role in the initiation, progression, and treatment of GC. This review elucidates the current understanding of the roles played by gastric microbiota and their metabolic products in the progression of GC. Additionally, it summarizes and prognosticates the translational value and clinical significance of gastric microbiota in the diagnosis, prognosis, and treatment of GC. The gastric microbiota assumes a dual role in the progression and treatment of GC. Further in-depth studies on the interactions and mechanisms between gastric microbiota and the host represent an emerging and valuable area in the field of GC research.

Indexed as

DysbiosisGastrointestinal MicrobiomeStomach NeoplasmsAnimalsDisease ProgressionHumansPrognosisDysbiosisGastric cancerGastric microbiotaTumor progressionTumor therapy

Identifiers

PMID42156610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.